Hims & Hers – Revenue Rocket, Profit Crash Landing: I Remain Skeptical and Await Proof!

I currently see two companies in Hims & Hers: an impressive growth story and a painful construction site. The raised revenue forecast of $3.1 to $3.3 billion sounds strong and is clearly above the market expectation of $2.93 billion – yet the adjusted loss of 37 cents instead of the expected 6 cents per share shows me how costly the forced restructuring really is. After the dispute with Novo Nordisk, the high-margin in-house production of GLP-1 analogs is lost, and the sale of approved branded goods is squeezing the margin. The new fantasy...